Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Purchased by Novo Holdings A S

Novo Holdings A S increased its stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 5.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,850,000 shares of the company's stock after purchasing an additional 100,000 shares during the quarter. Novo Holdings A S owned 4.29% of Kyverna Therapeutics worth $9,046,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. DekaBank Deutsche Girozentrale acquired a new stake in shares of Kyverna Therapeutics in the 1st quarter valued at approximately $181,000. Teachers Retirement System of The State of Kentucky raised its position in Kyverna Therapeutics by 69.7% in the second quarter. Teachers Retirement System of The State of Kentucky now owns 21,410 shares of the company's stock worth $161,000 after acquiring an additional 8,796 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in Kyverna Therapeutics by 32.6% in the second quarter. The Manufacturers Life Insurance Company now owns 37,794 shares of the company's stock worth $283,000 after acquiring an additional 9,300 shares in the last quarter. Skandinaviska Enskilda Banken AB publ lifted its holdings in Kyverna Therapeutics by 55.8% in the second quarter. Skandinaviska Enskilda Banken AB publ now owns 26,195 shares of the company's stock valued at $196,000 after acquiring an additional 9,385 shares during the period. Finally, Creative Planning purchased a new stake in shares of Kyverna Therapeutics during the 3rd quarter worth $54,000. 18.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. RODMAN&RENSHAW upgraded shares of Kyverna Therapeutics to a "strong-buy" rating in a report on Wednesday, October 9th. JPMorgan Chase & Co. dropped their target price on shares of Kyverna Therapeutics from $39.00 to $33.00 and set an "overweight" rating for the company in a report on Wednesday, July 31st. Rodman & Renshaw started coverage on Kyverna Therapeutics in a research note on Wednesday, October 9th. They set a "buy" rating and a $16.00 price target on the stock. UBS Group initiated coverage on Kyverna Therapeutics in a report on Thursday, October 10th. They issued a "buy" rating and a $13.00 price target on the stock. Finally, HC Wainwright reaffirmed a "neutral" rating and set a $7.00 price objective on shares of Kyverna Therapeutics in a report on Thursday, September 19th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $28.71.

Kyverna Therapeutics Stock Performance

Kyverna Therapeutics stock traded up $0.15 during mid-day trading on Friday, hitting $5.12. 199,389 shares of the company were exchanged, compared to its average volume of 476,528. Kyverna Therapeutics, Inc. has a 12-month low of $4.40 and a 12-month high of $35.06. The business's 50 day simple moving average is $6.27 and its two-hundred day simple moving average is $9.98.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.67) EPS for the quarter, topping analysts' consensus estimates of ($0.70) by $0.03. On average, analysts anticipate that Kyverna Therapeutics, Inc. will post -3.38 EPS for the current fiscal year.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.